Skip to main content
SpringerLink
Log in

Antibody-Based Biotherapeutics in Inflammatory Diseases

  • Chapter
  • First Online:
Pharmaceutical Biotechnology

  • 114k Accesses

Abstract

Inflammatory diseases encompass a broad and diverse spectrum of serious chronic disorders, many of which have significant need for safe and effective pharmacotherapies. The conventional drugs used to treat immune-mediated inflammatory diseases include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, sulfasalazine, 5-aminosalicylates, methotrexate, azathioprine, and 6-mercaptopurine which have exhibited limited efficacy with significant side effects. The initial rationale and promise of antibody-based biotherapeutics, such as monoclonal antibodies (mAbs), was focused on oncology and organ transplantation. Over the last two decades, there has been significant success in developing a number of antibody-based biotherapeutics as a very effective and relatively safe treatment for several inflammatory diseases, and this area of research and development is rapidly expanding. Five of the top-selling mAbs are for the treatment of chronic inflammatory conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abdallah H, Hsu JC, Lu P et al (2017) Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA. J Clin Pharmacol 57:459–468

    Article  CAS  PubMed  Google Scholar 

  • Actemra (tocilizumab) (2017) US prescribing information. Genentech Inc., South San Francisco

    Google Scholar 

  • Adedokun OJ, Xu Z, Padgett L et al (2013) Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study. Inflamm Bowel Dis 19:2753–2762

    Article  PubMed  Google Scholar 

  • Adedokun OJ, Sandborn WJ, Feagan BG et al (2014) Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 147:1296–1307.e5

    Article  CAS  PubMed  Google Scholar 

  • Adedokun OJ, Xu Z, Marano CW et al (2017) Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2/3 PURSUIT induction and maintenance studies. J Crohns Colitis 11:35–46

    Article  PubMed  Google Scholar 

  • Arcalyst (rilonacept) (2016) US prescribing information. Regeneron Pharmaceuticals Inc., Tarrytown

    Google Scholar 

  • Baumgart DC, Sandborn WJ (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369:1641–1657

    Article  CAS  PubMed  Google Scholar 

  • Benlysta (Belimumab) (2017) US prescribing information. Human Genome Sciences, Inc., (a subsidiary of GlaxoSmithKline), Rockville

    Google Scholar 

  • Blauvelt A, Reich K, Tsai TF et al (2017) Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol 76:60–69. e9

    Article  CAS  PubMed  Google Scholar 

  • Blok JL, Li K, Brodmerkel C, Horvátovich P, Jonkman MF, Horváth B (2016) Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol 174:839–846

    Article  CAS  PubMed  Google Scholar 

  • Boguniewicz M (2017) Biologic therapy for atopic dermatitis: moving beyond the practice parameter and guidelines. J Allergy Clin Immunol Pract 5:1477–1487

    Article  PubMed  Google Scholar 

  • Bongartz T, Sutton AJ, Sweeting MJ et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285

    Article  CAS  PubMed  Google Scholar 

  • Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ (2016) Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics 3:16011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Borrás-Blasco J, Casterá DE, Cortes X, Abad FJ, Rosique-Robles JD, Mallench LG (2015) Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults. Int J Clin Pharmacol Ther 53:377–390

    Article  PubMed  CAS  Google Scholar 

  • Brown SL, Greene MH, Gershon SK et al (2002) Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46:3151–3158

    Article  CAS  PubMed  Google Scholar 

  • Chaudhary R, Butler M, Playford RJ, Ghosh S (2006) Anti-TNF antibody induced stimulated T lymphocyte apoptosis depends on the concentration of the antibody and etanercept induces apoptosis at rates equivalent to infliximab and adalimumab at 10 micrograms per ml concentration. Gastroenterology 130(Suppl 2). [Abstract A696]

    Google Scholar 

  • Choi SL, Jackson K, Chigutsa E et al (2016) A longitudinal PKPD model describing the static Physician Global Assessment (sPGA) response to ixekizumab in patients with moderate to severe plaque psoriasis. J Pharmacokinet Pharmacodyn 43:S37. [Abstract M-57]

    Google Scholar 

  • Christophers E (2001) Psoriasis—epidemiology and clinical spectrum. Clin Exp Dermatol 26:314–320

    Article  CAS  PubMed  Google Scholar 

  • Cimzia (certolizumab pegol) (2016) US prescribing information. UCB Inc, Smyrna

    Google Scholar 

  • Cinqair (reslizumab) (2016) US prescribing information. Teva Pharmaceutical Industries Ltd., Frazer

    Google Scholar 

  • Cooke A, Bulkhi A, Casale T (2015) Role of biologics in intractable urticaria. Biologics 9:25–33

    CAS  PubMed  PubMed Central  Google Scholar 

  • Cosentyx (secukinumab) (2017) US prescribing information. Novartis Pharmaceuticals Corporation, East Hanover

    Google Scholar 

  • Davis JC, Mease PJ (2008) Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic. Semin Arthritis Rheum 38:83–100

    Article  CAS  PubMed  Google Scholar 

  • D’Haens G, Baert F, van Assche G et al (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 371:660–667

    Article  PubMed  CAS  Google Scholar 

  • Dupixent (dupilumab) (2017) US prescribing information. Sanofi-aventis U.S. LLC/ and Regeneron Pharmaceuticals, Inc., Bridgewater

    Google Scholar 

  • Ehrlich P (1891) Experimentelle untersuchungen über immunität. I. Ueber Ricin. Dtsch Med Wochenschr 17:976–979

    Article  Google Scholar 

  • Ellerin T, Rubin RH, Weinblatt ME (2003) Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 48:3013–3022

    Article  CAS  PubMed  Google Scholar 

  • Enbrel (etanercept) (2016) US prescribing information. Immunex Corporation, Thousand Oaks

    Google Scholar 

  • Entyvio (vedolizumab) (2014) US prescribing information. Takeda Pharmaceuticals, Deerfield

    Google Scholar 

  • European Medicines Agency (2009) EMEA/541561/2009- Assessment report (Arcalyst®). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001047/WC500026509.pdf. Accessed 06 Feb 2018

  • European Medicines Agency (2013a) EMA/56352/2013- Assessment report (Humira®). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000481/WC500138422.pdf. Accessed 06 Feb 2018

  • European Medicines Agency (2013b) EMA/CHMP/431551/2013- Assessment report (Stelara®). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000958/WC500150607.pdf. Accessed 06 Feb 2018

  • European Medicines Agency (2015a) EMA/CHMP/177541/2015- Extension of indication variation assessment report (Humira®). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000481/WC500186769.pdf. Accessed 06 Feb 2018

  • European Medicines Agency (2015b) EMA/CHMP/364731/2015- Assessment report (Humira®). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000481/WC500195564.pdf. Accessed 06 Feb 2018

  • European Medicines Agency (2015c) EMA/CHMP/665405/2015 - Assessment report (Cosentyx®). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/003729/WC500199574.pdf. Accessed 06 Feb 2018

  • European Medicines Agency (2015d) EMA/CHMP/665427/2015- Assessment report (Cosentyx®). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/003729/WC500199573.pdf. Accessed 06 Feb 2018

  • European Medicines Agency (2016a) EMA/501143/2016- Extension of indication variation assessment report (Humira®). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000481/WC500211228.pdf. Accessed 06 Feb 2018

  • European Medicines Agency (2016b) EMA/CHMP/404217/2016- Assessment report (Simponi®). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000992/WC500211888.pdf. Accessed 06 Feb 2018

  • European Medicines Agency (2017a) EMA/455579/2017- Assessment report (Orencia®). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000701/WC500233148.pdf. Accessed 06 Feb 2018

  • European Medicines Agency (2017b) EMA/512262/2017- Assessment report (Dupixent®). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004390/WC500236509.pdf. Accessed 06 Feb 2018

  • European Medicines Agency (2017c) EMA/790835/2017- Assessment report (Ocrevusi®). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004043/WC500241126.pdf. Accessed 06 Feb 2018

  • European Medicines Agency (2017d) EMA/CHMP/829007/2017- Assessment report (Humira®). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000481/WC500240431.pdf. Accessed 06 Feb 2018

  • Fasanmade A, Oison A, Bag W, Pendley C, Davis H, Mayer L (2002) Relationship between Infliximab Pharmacokinetics and Improvement in Crohn’s disease. Gastroenterology 122(Suppl 4):A617–A618. [Abstract W1364]

    Google Scholar 

  • Fasanmade AA, Marsters P, Munsanje E, Graham MA, Davis HM, Van Deventer S (2003) Infliximab pharmacokinetics and improvement in fistulizing Crohn’s disease. Gastroenterology 124(Suppl 1):A61. [Abstract 470]

    Article  Google Scholar 

  • Fasenra (benralizumab) (2017) US prescribing information. AstraZeneca Pharmaceuticals LP, Wilmington

    Google Scholar 

  • Feldman SR, Krueger GG (2005) Psoriasis assessment tools in clinical trials. Ann Rheum Dis 64(Suppl 2):ii65–ii68

    PubMed  PubMed Central  Google Scholar 

  • Gibiansky L, Gibiansky E, Frey N et al (2017) Population pharmacokinetic and exposure-efficacy/safety analyses for selection of optimal dose regimen of tocilizumab in patients with giant cell arteritis (GCA). J Pharmacokinet Pharmacodyn 44:S131. [Abstract W-076]

    Article  CAS  Google Scholar 

  • Golay J, Semenzato G, Rambaldi A et al (2013) Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs 5:826–837

    Article  PubMed  PubMed Central  Google Scholar 

  • Gold R, Jawad A, Miller DH et al (2007) Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol 187:156–158

    Article  CAS  PubMed  Google Scholar 

  • Gomez-Garcia F, Epstein D, Isla-Tejera B et al (2017) Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. Br J Dermatol 176:594–603

    Article  CAS  PubMed  Google Scholar 

  • Greco A, Rizzo MI, De Virgilio A et al (2015) Churg-Strauss syndrome. Autoimmun Rev 14:341–348

    Article  CAS  PubMed  Google Scholar 

  • Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370:263–271

    Article  CAS  PubMed  Google Scholar 

  • Griffiths CE, Strober BE, van de Kerkhof P et al (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362:118–128

    Article  CAS  PubMed  Google Scholar 

  • Gura T (2002) Therapeutic antibodies: magic bullets hit the target. Nature 417:584–586

    Article  CAS  PubMed  Google Scholar 

  • Hasegawa M, Imai Y, Hiraoka M, Ito K, Roy A (2011) Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn 38:803–832

    Article  CAS  PubMed  Google Scholar 

  • Hawkins PN, Lachmann HJ (2003) Interleukin-1-receptor antagonist in the Muckle–Wells syndrome. N Engl J Med 348:2583–2584

    Article  PubMed  Google Scholar 

  • Hochhaus G, Brookman L, Fox H et al (2003) Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 19:491–498

    Article  CAS  PubMed  Google Scholar 

  • Hoentjen F, van Bodegraven AA (2009) Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 15:2067–2073

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hoseyni HG, Xu Y, Zhou H (2018) Therapeutic drug monitoring (TDM) of biologics for inflammatory bowel disease – an answer to optimized treatment? J Clin Pharmacol 58(7):864–876

    Article  CAS  PubMed  Google Scholar 

  • Hsu LF, Huang JD (2014) Evaluation of etanercept dose reduction in patients with rheumatoid arthritis using pharmacokinetic/pharmacodynamic modeling and simulation. Int J Clin Pharmacol Ther 52:776–786

    Article  CAS  PubMed  Google Scholar 

  • Hu C, Xu Z, Zhang Y, Rahman MU, Davis HM, Zhou H (2011) Population approach for exposure-response modeling of golimumab in patients with rheumatoid arthritis. J Clin Pharmacol 51:639–648

    Article  CAS  PubMed  Google Scholar 

  • Hu C, Adedokun OJ, Chen Y et al (2017a) Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn’s disease. J Pharmacokinet Pharmacodyn 44:425–436

    Article  CAS  PubMed  Google Scholar 

  • Hu C, Randazzo B, Sharma A, Zhou H (2017b) Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients. J Pharmacokinet Pharmacodyn 44:437–448

    Article  CAS  PubMed  Google Scholar 

  • Humira (adalimumab) (2017) US prescribing information. AbbVie Inc, North Chicago

    Google Scholar 

  • Hutmacher MM, Nestorov I, Ludden T, Zitnik R, Banfield C (2007) Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasis. J Clin Pharmacol 47:238–248

    Article  CAS  PubMed  Google Scholar 

  • Ilaris (canakinumab) (2016) US prescribing information. Novartis Pharmaceuticals Corporation, East Hanover

    Google Scholar 

  • Jabbar-Lopez ZK, Yiu ZZN, Ward V et al (2017) Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Investig Dermatol 137:1646–1654

    Article  CAS  PubMed  Google Scholar 

  • Kevzara (sarilumab) (2017) US prescribing information. Sanofi-aventis U.S. LLC/Regeneron Pharmaceuticals, Inc., Bridgewater

    Google Scholar 

  • Khattri S, Brunner PM, Garcet S et al (2017) Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol 26:28–35

    Article  CAS  PubMed  Google Scholar 

  • Kraft M, Worm M (2017) Dupilumab in the treatment of moderate-to-severe atopic dermatitis. Expert Rev Clin Immunol 13:301–310

    Article  CAS  PubMed  Google Scholar 

  • Kubota T, Koike R (2010) Cryopyrin-associated periodic syndromes: background and therapeutics. Mod Rheumatol 20:213–221

    Article  PubMed  Google Scholar 

  • Lachmann HJ, Lowe P, Felix SD et al (2009) In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 206:1029–1036

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lacroix BD, Karlsson MO, Friberg LE (2014) Simultaneous exposure-response modeling of ACR20, ACR50, and ACR70 improvement scores in rheumatoid arthritis patients treated with certolizumab pegol. CPT Pharmacometrics Syst Pharmacol. 3:e143

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Laffaldano P, Lucchese G, Trojano M (2011) Treating multiple sclerosis with natalizumab. Expert Rev Neurother 11:1683–1692

    Article  CAS  Google Scholar 

  • Langford CA, Cuthbertson D, Ytterberg SR et al (2017) A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Giant cell arteritis. Arthritis Rheumatol 69:837–845

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Langley RG (2012) Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data? J Eur Acad Dermatol Venereol 26(Suppl 2):21–29

    Article  PubMed  Google Scholar 

  • Langley RG, Elewski BE, Lebwohl M et al (2014) Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med 371:326–338

    Article  PubMed  CAS  Google Scholar 

  • Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC (2003) Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 73:348–365

    Article  CAS  PubMed  Google Scholar 

  • Leonardi CL, Kimball AB, Papp KA et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665–1674

    Article  CAS  PubMed  Google Scholar 

  • Levi M, Grange S, Frey N (2013) Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis. J Clin Pharmacol 53:151–159

    Article  CAS  PubMed  Google Scholar 

  • Li X, Passarell JA, Lin K, Roy A, Murthy B, Girgis IG (2017) Population pharmacokinetics and exposure–response analyses for abatacept in juvenile idiopathic arthritis. J Pharmacokinet Pharmacodyn 44:S127–S128. [Abstract W-069]

    Google Scholar 

  • Lin P, Suhler EB, Rosenbaum JT (2014) The future of uveitis treatment. Ophthalmology 121:365–376

    Article  PubMed  Google Scholar 

  • Lowe PJ, Tannenbaum S, Gautier A, Jimenez P (2009) Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 68:61–76

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ma L, Xu C, Su Y, Paccaly A, Kanamaluru V (2016a) Population pharmacokinetics and pharmacodynamics of the effect of sarilumab on DAS28-CRP in patients with rheumatoid arthritis. J Pharmacokinet Pharmacodyn 43:S106. [Abstract W-46]

    Google Scholar 

  • Ma L, Xu C, Su Y, Paccaly A, Kanamaluru V (2016b) Population pharmacokinetics and pharmacodynamics of the effect of sarilumab on absolute neutrophil counts in patients with rheumatoid arthritis. J Pharmacokinet Pharmacodyn 43:S106–S107. [Abstract W-47]

    Google Scholar 

  • Mallipeddi R, Grattan C (2007) Lack of response of severe steroid-dependent chronic urticaria to rituximab. Clin Exp Dermatol 32:333–334

    Article  CAS  PubMed  Google Scholar 

  • Maurer M, Weller K, Bindslev-Jensen C et al (2011) Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 66:317–330

    Article  CAS  PubMed  Google Scholar 

  • McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205–2219

    Article  CAS  PubMed  Google Scholar 

  • Menting SP, Coussens E, Pouw MF et al (2015) Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis: a step toward personalized treatment. JAMA Dermatol. 151:616–622

    Article  PubMed  Google Scholar 

  • Modigliani R, Mary JY, Simon JF et al (1990) Clinical, biological, and endoscopic picture of attacks of Crohn’s disease: evolution on prednisolone. Gastroenterology 98:811–818

    Article  CAS  PubMed  Google Scholar 

  • Molodecky NA, Soon IS, Rabi DM et al (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142:46–54. e42

    Article  PubMed  Google Scholar 

  • Muralidharan KK, Kuesters G, Plavina T et al (2017a) Population pharmacokinetics and target engagement of natalizumab in patients with multiple sclerosis. J Clin Pharmacol 57:1017–1030

    Article  CAS  PubMed  Google Scholar 

  • Muralidharan KK, Steiner D, Amarante D et al (2017b) Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis. J Pharmacokinet Pharmacodyn 44:263–275

    Article  CAS  PubMed  Google Scholar 

  • Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361:496–509

    Article  CAS  PubMed  Google Scholar 

  • Nucala (mepolizumab) (2017) US prescribing information. GlaxoSmithKline LLC, Philadelphia

    Google Scholar 

  • O’Dell JR (2004) Therapeutic strategies for rheumatoid arthritis. N Engl J Med 350:2591–2602

    Article  PubMed  Google Scholar 

  • Orencia (abatacept) (2017) US prescribing information. Bristol-Myers Squibb Company, Princeton

    Google Scholar 

  • Ocrevus (ocrelizumab) (2017) US prescribing information. Genentech, Inc. A Member of the Roche Group, South San Francisco

    Google Scholar 

  • Papp KA, Langley RG, Lebwohl M et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371:1675–1684

    Article  CAS  PubMed  Google Scholar 

  • Papp K, Gulliver W, Lynde C et al (2011) Canadian guidelines for the management of plaque psoriasis. J Cutan Med Surg 15:210–219

    Article  PubMed  Google Scholar 

  • Polman CH, O’Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910

    Article  CAS  PubMed  Google Scholar 

  • Pradeep S, Smith JH (2018) Giant cell arteritis: practical pearls and updates. Curr Pain Headache Rep 22:2

    Article  PubMed  Google Scholar 

  • Reich K, Nestle FO, Papp K et al (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366:367–374

    Article  CAS  Google Scholar 

  • Reich K, Burden AD, Eaton JN, Hawkins NS (2012) Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol 166:179–188

    Article  CAS  PubMed  Google Scholar 

  • Remicade (infliximab) (2017) US prescribing information. Janssen Biotech Inc, Horsham

    Google Scholar 

  • Rituxan (rituximab) (2016) US prescribing information. Genentech Inc., South San Francisco

    Google Scholar 

  • Rosario M, Dirks NL, Gastonguay MR et al (2015) Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther 42:188–202

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rosario M, French JL, Dirks NL et al (2017) Exposure-efficacy relationships for vedolizumab induction therapy inp with ulcerative colitis or Crohn’s disease. J Crohns Colitis 11:921–929

    Article  PubMed  Google Scholar 

  • Roy A, Mould DR, Wang XF, Tay L, Raymond R, Pfister M (2017) Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. J Clin Pharmacol 47:1408–1420

    Article  CAS  Google Scholar 

  • Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus interferon-β-1a for relapsing multiple sclerosis. N Engl J Med 354:911–923

    Article  CAS  PubMed  Google Scholar 

  • Ruzicka T, Hanifin JM, Furue M et al (2017) Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med 376:826–835

    Article  CAS  PubMed  Google Scholar 

  • Saeki H, Kabashima K, Tokura Y et al (2017) Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomised, double-blind, placebo-controlled, phase II Study. Br J Dermatol 177:419–427

    Article  CAS  PubMed  Google Scholar 

  • Salinger DH, Endres CJ, Gibbs MA (2014) Exposure-response model of brodalumab in psoriasis: modeling of continuous PASI response predicts categorical PASI 75 and PASI 100 endpoints. J Pharmacokinet Pharmacodyn 41:S52–S53. [Abstract T-030]

    Google Scholar 

  • Salliot C, Finckh A, Katchamart W et al (2011) Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 70:266–271

    Article  CAS  PubMed  Google Scholar 

  • Sandborn WJ, Feagan BG, Stoinov S et al (2006) Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn’s disease: results from a 26-week, placebo-controlled phase III study (PRECiSE 1). Gastroenterology 130:A-107

    Google Scholar 

  • Shanmugam VK, Zaman NM, McNish S, Hant FN (2017) Review of current immunologic therapies for hidradenitis suppurativa. Int J Rheumatol 2017:8018192. https://doi.org/10.1155/2017/8018192

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Siliq (brodalumab) (2017) US prescribing information. Valeant Pharmaceuticals North America LLC, Bridgewater

    Google Scholar 

  • Simponi (golimumab) (2017a) US prescribing information. Janssen Biotech Inc, Horsham

    Google Scholar 

  • Simponi (golimumab) (2017b) European Union summary of product characteristics (SmPC). Janssen Biologics B.V, Leiden

    Google Scholar 

  • Simponi Aria (golimumab) (2017) US prescribing information. Janssen Biotech Inc, Horsham

    Google Scholar 

  • Smedby KE, Askling J, Mariette X et al (2008) Autoimmune and inflammatory disorders and risk of malignant lymphomas–an update. J Intern Med 264:514–527

    Article  CAS  PubMed  Google Scholar 

  • Smith DA, Minthorn EA, Beerahee M (2011) Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet 50:215–227

    Article  CAS  PubMed  Google Scholar 

  • Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER (2009) The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 330:864–875

    Article  CAS  PubMed  Google Scholar 

  • St Clair EW, Wagner CL, Fasanmade AA et al (2002) The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:1451–1459

    Article  CAS  PubMed  Google Scholar 

  • Stelara (ustekinumab) (2017) US prescribing information. Janssen Biotech Inc, Horsham

    Google Scholar 

  • Struemper H, Thapar M, Roth D (2018) Population pharmacokinetic and pharmacodynamic analysis of belimumab administered subcutaneously in healthy volunteers and patients with systemic lupus erythematosus. Clin Pharmacokinet 57(6):717–728.

    Article  PubMed Central  CAS  Google Scholar 

  • Sun H, Van LM, Floch D et al (2016) Pharmacokinetics and pharmacodynamics of canakinumab in patients with systemic juvenile idiopathic arthritis. J Clin Pharmacol 56:1516–1527

    Article  CAS  PubMed  Google Scholar 

  • Taltz (ixekizumab) (2017) US prescribing information. Eli Lilly and Company, Indianapolis

    Google Scholar 

  • Taylor PC, Steuer A, Gruber J et al (2004) Comparison of ultrasonographic assessment of synovitis and joint vascularity radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 50:1107–1116

    Article  CAS  PubMed  Google Scholar 

  • Ternant D, Ducourau E, Fuzibet P et al (2015) Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol 79:286–297

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tracey D, Klareskog L, Sasso EH et al (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117:244–279

    Article  CAS  PubMed  Google Scholar 

  • Tremfya (guselkumab) (2017) US prescribing information. Janssen Biotech Inc, Horsham

    Google Scholar 

  • Tysabri® (natalizumab) (2017) US prescribing information. Biogen Idec Inc, Cambridge

    Google Scholar 

  • Tzanetakou V, Kanni T, Giatrakou S et al (2016) Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol 152:52–59

    Article  PubMed  Google Scholar 

  • US Food and Drug Administration (2008) 125104Orig1s0033 [BLA#125104/33]- Clinical pharmacology/biopharmaceutics review (Tysabri®). https://www.accessdata.fda.gov/drugsatfda_docs/bla/2008/125104Orig1s0033.pdf. Accessed 06 Feb 2018

  • US Food and Drug Administration (2015a) Advisory Committee Briefing Document (BLA#761033, Reslizumab). https://www.fdanews.com/ext/resources/files/12-15/12-07-15-Teva-reslizumab.pdf?1517272698. Accessed 06 Feb 2018

  • US Food and Drug Administration (2015b) Clinical pharmacology/ Biopharmaceutics Review (Cosentyx®)-125504Orig1s000 (BLA#125504). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125504Orig1s000ClinPharmR.pdf. Accessed 06 Feb 2018

  • Van den Brande JM, Braat H, van den Brink GR et al (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 124:1774–1785

    Article  PubMed  CAS  Google Scholar 

  • Vande Casteele N, Feagan BG, Vermeire S et al (2018) Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn’s disease. Aliment Pharmacol Ther 47:229–237

    Article  CAS  PubMed  Google Scholar 

  • Vestergaard C, Deleuran M (2015) Chronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapy. Ther Adv Chronic Dis 6:304–313

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vogelzang EH, Kneepkens EL, Nurmohamed MT et al (2014) Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis 73:2178–2182

    Article  CAS  PubMed  Google Scholar 

  • Vogelzang EH, Pouw MF, Nurmohamed M et al (2015) Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs. Ann Rheum Dis. 74:474–475

    Article  CAS  PubMed  Google Scholar 

  • Wang B, Yan L, Yao Z, Roskos LK (2017) Population pharmacokinetics and pharmacodynamics of benralizumab in healthy volunteers and patients with asthma. CPT Pharmacometrics Syst Pharmacol 6:249–257

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wolbink G, Goupille P, Sandborn W et al (2016) Association between plasma certolizumab pegol concentration and improvement in disease activity in rheumatoid arthritis and Crohn’s disease. Arthritis Rheumatol 68(Suppl 10). [Abstract 596]

    Google Scholar 

  • Xiong Y, Wang W, Ebling W et al (2013) Exposure-response modeling of canakinumab in the avoidance of flares in children with systemic juvenile idiopathic arthritis. Pediatr Rheumatol 11(Suppl 2):P181. [Abstract]

    Article  Google Scholar 

  • Xolair (omalizumab) (2016) US prescribing information. Genentech Inc., South San Francisco

    Google Scholar 

  • Zhang X, Morcos PN, Saito T, Terao K (2013) Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis. Expert Rev Clin Pharmacol 6:123–137

    Article  CAS  PubMed  Google Scholar 

  • Zhang X, Chen YC, Terao K (2017) Clinical pharmacology of tocilizumab for the treatment of polyarticular-course juvenile idiopathic arthritis. Expert Rev Clin Pharmacol 10:471–482

    Article  CAS  PubMed  Google Scholar 

  • Zheng Y, Le K, Wada R et al (2014) Population PK-PD and exposure–response modeling and simulation to support dose recommendation of Xolair in chronic idiopathic urticaria/chronic spontaneous urticaria. J Pharmacokinet Pharmacodyn 41:S32. [Abstract M-059]

    Google Scholar 

  • Zhou H, Hu C, Zhu Y et al (2010) Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 50:257–267

    Article  CAS  PubMed  Google Scholar 

Suggested Readings

  • Lagassé HA, Alexaki A, Simhadri VL, Katagiri NH, Jankowski W, Sauna ZE, Kimchi-Sarfaty C (2017) Recent advances in therapeutic protein drug development. F1000Res 6:113. https://doi.org/10.12688/f1000research.9970.1.eCollection2017

    Article  PubMed  PubMed Central  Google Scholar 

  • Murphy K, Weaver C (2016) Janeway’s Immunology. 9th edn. Garland Science. ISBN: 978-0815345053

    Google Scholar 

  • Zhou H, Theil F-P (eds) (2015) ADME and Translational Pharmacokinetics/Pharmacodynamics of Therapeutic Proteins. John Wiley and Sons, Inc., Hoboken. ISBN: 978-1-118-89864-2

    Google Scholar 

  • Zhou H, Mould D (eds) (2019) Quantitative pharmacology and individualized therapy strategies in development of therapeutic proteins for immune-mediated inflammatory diseases. Wiley, Hoboken. ISBN: 978-1119289197

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacology and Pharmacometrics, Janssen Research and Development, Spring House, PA, USA

    Honghui Zhou, Yan Xu & Amarnath Sharma

Authors
  1. Honghui Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amarnath Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Honghui Zhou .

Editor information

Editors and Affiliations

  1. Utrecht University, Utrecht, The Netherlands

    Daan J. A. Crommelin

  2. Faculty of Pharmaceutical Sciences and The Centre for Health Evaluation & Outcomes Sciences (CHEOS), The University of British Columbia (UBC), Vancouver, BC, Canada

    Robert D. Sindelar

  3. College of Pharmacy, University of Tennessee, Health Science Center, Memphis, TN, USA

    Bernd Meibohm

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zhou, H., Xu, Y., Sharma, A. (2019). Antibody-Based Biotherapeutics in Inflammatory Diseases. In: Crommelin, D., Sindelar, R., Meibohm, B. (eds) Pharmaceutical Biotechnology. Springer, Cham. https://doi.org/10.1007/978-3-030-00710-2_26

Download citation

Publish with us

Policies and ethics

Search

Navigation